Press Releases Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Delayed Hong Kong S.E. Other stock markets 04:08:11 2024-05-08 EDT			5-day change	1st Jan Change
19.1 ^HKD	-1.14%		+6.82%	-30.04%

04-25	Ascentage Pharma to Present Four Studies at US Oncology Meet	MT
04-09	Ascentage Pharma Chairman Boosts Stake in Firm	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascentage Pharma Announces 2023 Annual Results	03-28	AQ
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA	02-13	PR
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference	01-01	PR
Live from ASH 2023, Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R MM, Demonstrating Encouraging ORR and VGPR	12-12	AQ
Live from ASH 2023, Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib	12-12	AQ
Live from ASH 2023, Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%	12-12	AQ
Small Lymphocytic Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 \| Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, and others.	12-05	AQ
Live from ESMO 2023 \| Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC	23-10-23	PR
Ascentage Pharma - First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naive Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	23-10-18	AQ
First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)	23-10-17	PR
Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax in Previously Treated Patients with CLL/SLL	23-08-07	AQ
Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with CLL/SLL	23-08-06	PR
ESMO 2023 \| Ascentage Pharma to Present Results from Two Clinical Studies, including One Oral Presentation, at 2023 ESMO Congress	23-08-02	PR
Ascentage Pharma has been listed in the TOP30 list of China's small molecule drug companies in terms of innovation power for three consecutive years, ranking among the top ten	23-06-30	AQ
BTD for the second time, Ascentage Pharma's Nelix is planned to be included in the breakthrough therapy category for the treatment of SDH-deficient GIST	23-06-01	AQ
Ascentage Pharma Passes GMP Compliance Audit by EU QP with Zero Deficiency, in an Achievement Signaling Global Recognition of the Company's Quality Management System	23-04-24	PR
Three research results of Ascentage Pharma presented at the 2023 American Association for Cancer Research Annual Meeting to explore more treatment possibilities	23-04-19	AQ
Ascentage Pharma Appoints Mr. Zhu Yifei as Chief Commercial Officer to Accelerate Commercialization Process	23-04-03	AQ
Ascentage Pharma Announces 2022 Annual Results Including Strong Sales of Olverembatinib and Steady Progress in Transition towards Biopharma	23-03-23	AQ
Ascentage Pharma was included in the Shanghai-Hong Kong Stock Connect, effective from March 13	23-03-08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Press Releases

Filters